data + articles · 2 listed
newest 2010spec sheet6 rows
S-18986 was French pharmaceutical company Servier's entry into the ampakine race, developed through the 2000s as a cognitive enhancer aimed squarely at age-related memory decline and Alzheimer's disease. The preclinical dossier was genuinely broad, covering procedural, spatial, episodic, working, and relational memory tasks in both young-adult and aged rodents, plus measurable increases in hippocampal BDNF and reduced oxidative stress markers in old rats. But like nearly every AMPA potentiator before it, the leap from rodent memory tasks to convincing human cognitive data never happened; a review co-authored by Servier's own researchers in 2010 candidly noted that no AMPA potentiator had yet demonstrated real clinical efficacy. S-18986 faded out of the literature not long after, without a publicized trial failure, just a quiet stop.
- Broad-spectrum memory improvement across multiple task types in aged rodents
- Increased hippocampal BDNF expression
- Reduced oxidative stress markers in aged rat brain
- Enhanced hippocampal long-term potentiation
- S-18986 was tested across procedural, spatial, episodic, working, and relational memory tasks in rodents, one of the broadest memory-domain dossiers of any ampakine.
- A 2010 review co-authored by Servier researchers openly admitted that no AMPA potentiator had yet shown real clinical efficacy, a rare moment of candor about the whole drug class.
Mechanism
Selective positive modulator of -type receptors; slows receptor desensitization, which increases hippocampal induction and maintenance and drives activity-dependent release.
Safetyrisks and cautions, not medical advice
Rodent studies are the entire record. No completed human trial of S-18986 has been published, which means no dose has been established in people, no adverse event list exists, and where the tolerable ceiling sits is anyone's guess. The aged-rat work reported memory gains without noting toxicity, but cognition studies in rats are not built to find toxicity. As an AMPA potentiator it inherits the class concern about overexcitation and seizures at high exposure, a concern explicitly measured for other members of the family and never publicly resolved for this one.
History
Characterized through the mid-to-late 2000s; key papers include a 2008 aged-rat cognition and oxidative stress study and a 2010 CNS Neuroscience & Therapeutics review by Servier-affiliated authors. No completed human efficacy trial was ever published.
Subjective profileweighing the evidence above
A thorough, honest preclinical cognitive-enhancer program that ran into the same wall every ampakine has hit; rodent memory data that never translated into a human trial worth publishing.
Resources
This entry is here for reference.
Research
- 1.Effects of the AMPA receptor modulator S 18986 on measures of cognition and oxidative stress in aged rats
- 2.DRUG FOCUS: S 18986: A Positive Allosteric Modulator of AMPA-Type Glutamate Receptors, Pharmacological Profile of a Novel Cognitive Enhancer
2 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Did S-18986 ever get tested in Alzheimer's patients?
There's no published record of a completed human efficacy trial. The compound has an extensive rodent dossier but the jump to confirmed clinical benefit never happened publicly.
Who developed S-18986?
Servier, the French pharmaceutical company, developed it in the 2000s as part of the broader ampakine cognitive-enhancer wave aimed at aging and Alzheimer's-related memory loss.
Limitations of the evidence
- No confirmed human efficacy or safety data was published
- Development appears to have quietly stopped without a public trial failure announcement